- Home
- AKRO vs EVT Comparison
AKRO vs EVT Comparison
Compare AKRO & EVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- EVT
- Stock Information
- Founded
- AKRO 2017
- EVT 2003
- Country
- AKRO United States
- EVT United States
- Employees
- AKRO N/A
- EVT N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- EVT Finance Companies
- Sector
- AKRO Health Care
- EVT Finance
- Exchange
- AKRO Nasdaq
- EVT Nasdaq
- Market Cap
- AKRO 3.9B
- EVT 1.7B
- IPO Year
- AKRO 2019
- EVT N/A
- Fundamental
- Price
- AKRO $51.77
- EVT $24.40
- Analyst Decision
- AKRO Strong Buy
- EVT
- Analyst Count
- AKRO 6
- EVT 0
- Target Price
- AKRO $82.50
- EVT N/A
- AVG Volume (30 Days)
- AKRO 1.7M
- EVT 115.5K
- Earning Date
- AKRO 08-08-2025
- EVT 01-01-0001
- Dividend Yield
- AKRO N/A
- EVT 8.32%
- EPS Growth
- AKRO N/A
- EVT N/A
- EPS
- AKRO N/A
- EVT 6.63
- Revenue
- AKRO N/A
- EVT $69,404,302.00
- Revenue This Year
- AKRO N/A
- EVT N/A
- Revenue Next Year
- AKRO N/A
- EVT N/A
- P/E Ratio
- AKRO N/A
- EVT $3.55
- Revenue Growth
- AKRO N/A
- EVT N/A
- 52 Week Low
- AKRO $21.02
- EVT $19.20
- 52 Week High
- AKRO $58.40
- EVT $25.83
- Technical
- Relative Strength Index (RSI)
- AKRO 48.51
- EVT 71.34
- Support Level
- AKRO $51.08
- EVT $23.89
- Resistance Level
- AKRO $57.35
- EVT $23.75
- Average True Range (ATR)
- AKRO 2.17
- EVT 0.25
- MACD
- AKRO -0.82
- EVT 0.07
- Stochastic Oscillator
- AKRO 8.17
- EVT 94.92
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.